[PDF][PDF] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of …

MJ Moore, D Goldstein, J Hamm, A Figer… - Journal of clinical …, 2007 - Citeseer
MJ Moore, D Goldstein, J Hamm, A Figer, JR Hecht, S Gallinger, HJ Au, P Murawa, D Walde…
Journal of clinical oncology, 2007Citeseer
Purpose Patients with advanced pancreatic cancer have a poor prognosis and there have
been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic
tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and
this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-
targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or
metastatic pancreatic cancer.
Purpose
Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.
Citeseer